NASDAQ:CORI Corium International (CORI) Stock Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free CORI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$12.68▼$12.6850-Day Range N/A52-Week Range$7.17▼$13.93VolumeN/AAverage Volume577,723 shsMarket Capitalization$459.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Corium International alerts: Email Address Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Corium International Stock (NASDAQ:CORI)Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.Read More Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here CORI Stock News HeadlinesJanuary 22, 2024 | ca.finance.yahoo.comQUEBEC AI INNOVATION: COGINOV AND CORIUM JOIN FORCES FOR ACCELERATED GROWTHAugust 10, 2023 | businesswire.comCorium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across AsiaApril 24, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.July 6, 2023 | investopedia.comBest International Student LoansMay 23, 2023 | travel.usnews.comThe 5 Best International Travel Insurance Companies for 2023May 15, 2023 | marketwatch.comGlobal 2023, Passive Transdermal Drug Delivery Market Analysis of New Report 2030April 28, 2023 | marketwatch.comPassive Transdermal Drug Delivery Market Share by 2031April 21, 2023 | marketwatch.comPassive Transdermal Drug Delivery Market Research, 2023-2030April 24, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.March 30, 2023 | marketwatch.com2023 Passive Transdermal Drug Delivery Market Size, Growth | Global Industry Trends [2029]March 30, 2023 | marketwatch.comVaccine Delivery Devices Market Share and Forecast till 2031March 28, 2023 | marketwatch.comPassive Transdermal Drug Delivery Market Share Likely to Grow At a Impressive CAGRMarch 18, 2023 | marketwatch.comMicroneedle Flu Vaccine Market: Forecast for 2023-2028 with Emerging TechnologiesMarch 15, 2023 | marketwatch.comPassive Transdermal Drug Delivery Market | Global Various Tendencies Industry Report, 2029March 13, 2023 | marketwatch.comVaccines Delivery Devices Market Share, Trends, Growth, Size and Segmentation by 2023 to 2028March 11, 2023 | marketwatch.com2023-2028 Vaccines Delivery Devices Market Size Report: Global Growth Drivers and Market Share AnalysisMarch 6, 2023 | msn.comHow a hobby turned into a successful business for Corium Skincare's Vuyi ZondiMarch 1, 2023 | finance.yahoo.comCorium Pharma Solutions Names Suzanne Hinchliffe as Chief People OfficerFebruary 23, 2023 | marketwatch.comVaccine Delivery Devices Market 2023 : Incredible Possibilities, Growth Analysis and Forecast To 2028February 22, 2023 | marketwatch.comPassive Transdermal Drug Delivery Market is Booming in Near Future 2023-2028February 10, 2023 | marketwatch.comPassive Transdermal Drug Delivery Market 2023 Structure Along With Size, Trends, Revenue, Market segments, Forecast to 2029February 8, 2023 | benzinga.comGlobal Alzheimer's Disease Therapeutics Market Research Report 2023: Forecasts, Epidemiology & Pipeline Analysis 2022-2028December 8, 2022 | marketwatch.comPassive Transdermal Drug Delivery Market : Research Report Provides an In-Depth Insight of Trends 2022 To 2028November 10, 2022 | msn.comBiogen picks Christopher Viehbacher, former leader of Sanofi, as new CEOAugust 23, 2022 | marketwatch.comClonidine Market Size and Share 2022 Analysis Report by Key Players, Geographical Regions, Future Development and Forecast to 2028August 20, 2022 | msn.comTrial results show promise for new Alzheimer’s skin patchAugust 3, 2022 | yahoo.comGluBio Completes Series A+ Financing of $22 Million to Advance the Development of Novel TPD DrugsSee More Headlines Receive CORI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corium International and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2018Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CORI CUSIPN/A CIK1594337 Webwww.coriumgroup.com Phone650-298-8255FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,790,000.00 Net Margins-155.21% Pretax MarginN/A Return on Equity-276.89% Return on Assets-57.52% Debt Debt-to-Equity Ratio2.83 Current Ratio7.61 Quick Ratio7.47 Sales & Book Value Annual Sales$31.86 million Price / Sales14.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book28.18Miscellaneous Outstanding Shares36,250,000Free FloatN/AMarket Cap$459.65 million OptionableOptionable Beta0.87 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Peter D. Staple (Age 66)Pres, CEO & Director Mr. Robert S. Breuil (Age 56)Chief Financial Officer Dr. Parminder Singh (Age 54)CTO & VP of R&D Mr. Timothy D. Sweemer CPAChief Accounting Officer, VP of Admin. & Sec.Ms. Christina DickersonVP of Corp. Devel.Key CompetitorsAdlai NortyeNASDAQ:ANLFulcrum TherapeuticsNASDAQ:FULCIGM BiosciencesNASDAQ:IGMSAcelyrinNASDAQ:SLRNShattuck LabsNASDAQ:STTKView All Competitors CORI Stock Analysis - Frequently Asked Questions How were Corium International's earnings last quarter? Corium International, Inc. (NASDAQ:CORI) released its quarterly earnings data on Thursday, August, 9th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.04. The biopharmaceutical company earned $7.67 million during the quarter, compared to analyst estimates of $6.72 million. Corium International had a negative trailing twelve-month return on equity of 276.89% and a negative net margin of 155.21%. What other stocks do shareholders of Corium International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corium International investors own include Intelsat (I), Iovance Biotherapeutics (IOVA), Aralez Pharmaceuticals (ARLZ), Cypress Semiconductor (CY), Energy Transfer (ET), Exelixis (EXEL), AMC Entertainment (AMC), Global Blood Therapeutics (GBT), SunCoke Energy Partners (SXCP) and Zynga (ZNGA). This page (NASDAQ:CORI) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corium International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
